embedded archival prostate tissue specimens (n = 1043) from radical prostatectomy (95.5%) or transurethral resection of the prostate (TURP) procedures (4.5%). The study was approved by the human subjects committee of the Harvard T.H. Chan School of Public Health, Boston, MA. Details of the prostate tumor cohort are available elsewhere. 15 Within the tissue cohort, 890 specimens were reviewed for chronic inflammation and 395 were reviewed for corpora amylacea; these subgroups were similar to the full tumor tissue cohort in terms of diagnosis year, age at diagnosis, PSA, and pathological Gleason score. Our study sample was restricted to men whose prostate tissue was reviewed for chronic inflammation and corpora amylacea (n = 355).
| Evaluation of histology data: Gleason grade, inflammation, and corpora amylacea
Study pathologists reviewed all available hematoxylin and eosin (H&E) slides of archival radical prostatectomy and TURP specimens to Within each H&E slide, areas of PIN, post-atrophic hyperplasia (PAH), and areas of >95% tumor glands were noted and manually encircled on the slides by the study pathologists. Among 395 participants, all available H&E slides (n = 1575 slides) were reviewed for corpora amylacea by trained investigators, who were not pathologists, using the 10x objective of a microscope (Labomed CXL, Labo America, Inc., Fremont, CA). The number of slides viewed per participant ranged from 1 to 37 slides, with a median of three slides per participant (IQR: 2-4) though the majority of the participants (81.77%) had ≤4 slides reviewed. The trained investigators counted the number of corpora amylacea for up to fifty-10× fields in the benign area. For example, a random field was selected to begin manually counting corpora amylacea and then we moved to an adjacent field to assess presence of corpora amylacea, and repeated for up to 50 fields in the benign tissue area. Similarly, within the encircled areas of predominately tumor glands, the trained investigators counted the number of corpora amylacea for up to fifty-10× fields; however, it was not distinguished whether the corpora amylacea within the predominately tumor area were found within an admixed benign gland or the tumor gland. The median of the total number of fields reviewed per participant in the benign area was 100 fields (IQR: 50-156) and the vasectomy status to better describe corpora amylacea and its potential drivers or consequences. We used the missing indicator method for those with missing PSA at diagnosis (n = 38) and missing acute inflammation data (n = 7), and used simple single imputation to assign values for those with missing TMPRSS2:ERG fusion status (n = 3), vasectomy (n = 1), and BMI at diagnosis (n = 1). 25 The missingness of PSA was primarily among cases diagnosed before 1994, which suggests that most individuals missing PSA were diagnosed in the pre-PSA screening era. In multivariable logistic regression models, we and vasectomy status at diagnosis (ever vs never). We further considered the proliferative index and angiogenesis biomarkers in the multivariable models using categories based on the median value cut-offs of the ki67 marker of cellular proliferation (high expression, low expression, and missing), vessel size (large diameter >24.8 µm, small diameter ≤24.8 µm, and missing) or vessel irregularity (most roundly shaped vessels, most irregularly shaped vessels, and missing). In supplementary analyses, we used multinomial logistic regression to test whether chronic inflammation was similarly associated with density and size of corpora amylacea in benign tissue after multivariable adjustment. We categorized corpora amylacea density as absent, present with low-density, or present with high-density based on the median value of corpora amylacea density. Furthermore, we categorized size of corpora amylacea as absent, present with generally small size, present with generally medium size, and present with generally large or various sizes.
| RESULTS
We found that 298 men (84%) had corpora amylacea in benign prostate tissue and 180 men (53%) had corpora amylacea within the predominately tumor area. Just over half of the men (51%) had corpora amylacea in both benign and predominately tumor areas, while corpora amylacea were absent in benign or tumor tissue for 14%. Clinical and histological characteristics of this cohort are displayed in Table 1 according to presence of corpora amylacea in the benign area. The corpora amylacea were predominately medium-sized. Images of the corpora amylacea in benign tissue and within the predominately-tumor area are presented in Supplementary Figure S1 .
The presence of chronic inflammation was strongly associated with corpora amylacea in benign tissue in the parsimonious (Table 2) and fully adjusted models (Supplementary Table S1 ). Compared to those without chronic inflammation, the multivariable odds ratios for presence of corpora amylacea were 3.3 for mild chronic inflammation (95%CI 1.3, 8.5) and 5.4 for moderate/severe chronic inflammation (95%CI 1.9, 15.6) (p-trend = 0.007, Table 2 ); findings were similar after accounting for additional covariates (Supplementary Table S1 ). These strong and positive associations with moderate-to-severe chronic inflammation were similar across levels of corpora amylacea density (Supplementary   Table S2 ) and size categories (Supplementary Table S3 ), albeit there were few with large-or various-sized corpora amylacea.
BMI was also positively associated with presence of corpora amylacea in benign tissue, with 1.13 times higher odds of having corpora amylacea for every 1 kg/m 2 increase in BMI at diagnosis (95% CI 1.01, 1.26; P-value = 0.03, P-value for trend = 0.14).
Patients with corpora amylacea in benign tissue had tumors that were characterized by less aggressive disease based on lower Gleason grade and lower ki67 proliferative index in the parsimonious (Table 2) and fully adjusted models (Supplementary Table S1 ). The presence of Table 2 ). In contrast,
there was a suggestion that PTEN loss was positively associated with presence of corpora amylacea (OR = 2.0 95%CI 0.8, 5.2, P-value = 0.16, Table 2 ) but this was not statistically significant.
Those with TURP specimens were much less likely to have corpora amylacea in benign tissue than those with radical prostatectomy tissue (OR = 0.12 95%CI 0.03, 0.47; P-value = 0.002, Table 2 ). There was a suggestion that older age at diagnosis (OR = 1.04 95%CI 0.99, 1.10; Pvalue = 0.13) was positively associated with corpora amylacea ( The sample size does not sum to the total sample size due to missingness of PSA. The percentages presented here are only among those with non-missing data. b The proliferation index, angiogenesis, and PTEN biomarkers were only measured on a subset of participants so the sample sizes do not sum to the total sample size with information on corpora amylacea in the benign-tissue area. The percentages presented here are only among those with biomarker data. 
| DISCUSSION
In this prostate cancer patho-epidemiology study, we found that corpora amylacea within the benign-area and within predominately tumor area was a more common histological feature among men with prostate cancer than previous reports. 11 -13 Furthermore, presence of corpora amylacea in benign tissue was strongly associated with proinflammatory factors (ie, moderate-to-severe chronic inflammation and higher BMI), as well as some markers of less aggressive prostate cancer (ie, lower Gleason and lower proliferative index), and with tumors that lack the TMPRSS2:ERG fusion ( Table 3 ). The associations were similar when we considered the density and size of corpora amylacea, highlighting that their presence alone is informative.
In the current study of prostatectomy and TURP tissue specimens, we found that a large majority of prostate cancer patients have corpora amylacea in adjacent normal tissue. We also observed that corpora amylacea were commonly found within the predominately tumor area;
however, we did not distinguish whether the corpora amylacea were within a tumor gland or a benign gland admixed in the tumor area, which may overestimate the prevalence of corpora amylacea in the predominately tumor area. In this study, the small TURP specimens were much less likely to have corpora amylacea compared to the whole-section radical prostatectomy tissue specimens. While this finding may be due to sampling variation, it is noteworthy that the TURP tissue tends to derive from the transitional zone of the prostate, whereas we quantified corpora amylacea predominantly in the peripheral zone of the prostatectomy specimens, which may suggest that corpora amylacea are more commonly found in the peripheral zone of the prostate.
Pro-inflammatory factors, especially chronic inflammation in the prostate, were associated with corpora amylacea. Corpora amylacea in the prostate are mainly composed of proteins involved in acute inflammatory and immune processes including lactoferrin, calprotectin, neutrophil-derived proteins (myeloperoxidase, α-defensins), β-microglobulin, and pro-inflammatory calcium-binding S100 proteins. 7, 26 Though the current cross-sectional study cannot distinguish the temporality of acute or chronic inflammation and corpora amylacea formation, the molecular structure of corpora amylacea suggest that their development is dependent on acute inflammatory proteins, immune proteins, and metal ions like Zn 2+ and Ca 2+ . 7, 9, 27 Interestingly, the strong association between chronic inflammation and corpora amylacea persisted after adjustment for acute inflammation among this group of men with prostate cancer. While it appears that the formation of corpora amylacea is dependent on existing inflammation, some hypothesize that corpora amylacea may also induce additional physical trauma to the surrounding prostatic cells perpetuating the inflammatory response (ie, positive feedback). 3 If corpora amylacea caused additional inflammatory trauma to the surrounding cells, one would expect stronger associations with chronic inflammation among those with higher density of corpora amylacea or larger-size corpora amylacea and not as strong associations with chronic inflammation among those with less dense or smaller-sized corpora amylacea. Our exploration of corpora amylacea density and size were consistent with the main finding that moderate-to-severe chronic inflammation was strongly associated with presence of corpora amylacea compared to those without chronic inflammation; however, we observed that the associations with chronic inflammation were not substantially different across high versus low density or across sizes of corpora amylacea.
The findings of corpora amylacea density and size show that chronic inflammation was similarly associated with presence of corpora amylacea regardless of the density or size, which would suggest that corpora amylacea were not causing additional damage and inflammation to the surrounding tissue; however, the findings on density and size are not conclusive given the small sample sizes for those within levels of density and size. Furthermore, BMI was a modest, independent predictor of presence of corpora amylacea in benign prostate tissue, even after adjusting for histological chronic inflammation. Obesity is marked by a chronic inflammatory condition whereby adipocytes secrete cytokines and experience phagocytosis. 28, 29 The associations with chronic inflammation and BMI highlight that corpora amylacea are related to pro-inflammatory exposures and that there are potentially modifiable factors contributing to the inflammatory environment of the prostate.
These observations that presence of corpora amylacea was common and associated with less aggressive disease markers, and with tumors that do not harbor the TMPRSS2:ERG fusion are hypothesis generating. While this cross-sectional study cannot tease apart temporality, these findings suggest that corpora amylacea formation may be a normal response to early cancers and the corpora amylacea may act to consolidate inflammatory debris to prevent more aggressive or mutated tumors; or perhaps the TMPRSS2:ERG fusion and aggressive tumors work to prevent the formation of corpora amylacea.
Limited literature suggests that TMPRSS2:ERG fusion-positive tumors are characterized by presence of inflammatory markers [30] [31] [32] [33] [34] and that inflammation was associated with worse disease. 4,5 TMPRSS2:ERG fusion-positive tumors had higher IL-6 expression than fusionnegative tumors 33 and the pro-tumorigenic effects of the NF-kB pathway were activated only in fusion-positive cancer patients. 32 Furthermore, inflammation-related exposures such as body mass index, [35] [36] [37] aspirin, and lycopene intake 38, 39 were associated with TMPRSS2:ERG fusion positive tumors and not fusion negative tumors.
In this study, we found that TMPRSS2:ERG fusion-positive tumors were less likely to have corpora amylacea, suggesting that the fusion positive tumors could be evading a normal process that may protect cells from inflammation. However, the cross-sectional design of this study restricts us drawing conclusions about the temporal relationship of corpora amylacea and tumor formation. While the debate continues on whether corpora amylacea are protective or degenerative, research on corpora amylacea in the brain also points to their role in defending cells from further damage. 8 This study has several limitations and strengths to consider when interpreting the study findings. The cross-sectional design of this study prohibits understanding the temporal development of prostatic corpora amylacea and their complex temporal relationship with the cellular environment. For example, corpora amylacea are composed of acute inflammatory proteins, 7 suggesting that their development depends on acute inflammation; however, in this cross-sectional study we could not fully distinguish the associations between acute inflammation and corpora amylacea independent of chronic inflammation as most men with prostate cancer who had acute inflammation also had chronic inflammation.
Similarly, in a cross-sectional study, one cannot distinguish whether the predictors influence development of corpora amylacea or if corpora amylacea may influence certain histological and tumor biomarkers. We did not measure the proximity of inflammatory infiltrates to the corpora amylacea, which would provide more compelling evidence for the relationship between inflammation and corpora amylacea; however, we still observed strong associations between chronic inflammation and corpora amylacea presence in benign tissue. The corpora amylacea found in predominately tumor area were not fully characterized as being within a tumor gland or being within a benign gland admixed in the tumor area, which can lead to misclassification and overestimation of corpora amylacea in the tumor area. Furthermore, while this is the first study to incorporate the size of corpora amylacea, the supplementary results on corpora amylacea size should be interpreted with caution because of small sample sizes and corpora amylacea size was not objectively measured that may lead to misclassification of size. In spite of these limitations, this was the first patho-epidemiologic study to assess corpora amylacea in prostatectomy and TURP tissue specimens and to incorporate a wealth of data to gain insight in to their formation and function. We used an array of biomarkers, clinical, histological, and lifestyle factors to characterize their cross-sectional associations with presence, density, and size of corpora amylacea. To our knowledge, this is the largest and most comprehensive epidemiologic study of prostatic corpora amylacea and provides novel insights on the biology of corpora amylacea.
In conclusion, the presence of corpora amylacea in prostatectomy tissue was common among men with prostate cancer and was strongly associated with chronic inflammation and obesity. Additionally, having corpora amylacea in the benign prostate tissue was associated with markers of less aggressive disease and lacking the TMPRSS2:ERG fusion in tumors. Further research is needed to establish the temporality in corpora amylacea formation and to understand the complex nature of inflammatory responses and the immune system in relation to molecular subtypes of prostate cancer. Investigators Awards to LAM, JRR, and the NCI T32 CA09001 to NCD.
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